BCR and acute lymphoblastic leukemia: Unsurprisingly, we observed expression of BCR::ABL1 translocations as this fusion is characteristic of B-ALL and a well-known oncogenic fusion protein that is presently treated with imatinib, a tyrosine kinase inhibitor [42].